Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus anlotinib in CDK4/6 inhibitor–resistant HR+ HER2- advanced breast cancer
ChiCTR2400092967Phase 2Not yet recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib and anlotinib in breast cancer, sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoints: Progression-free survival and Objective response rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
palbociclibanlotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400092967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092967.